vs
Side-by-side financial comparison of Angel Oak Mortgage REIT, Inc. (AOMR) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $10.9M, roughly 1.3× Angel Oak Mortgage REIT, Inc.). Angel Oak Mortgage REIT, Inc. runs the higher net margin — 103.9% vs -34.7%, a 138.6% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 10.4%). Over the past eight quarters, Angel Oak Mortgage REIT, Inc.'s revenue compounded faster (12.7% CAGR vs -26.3%).
Angel Oak Mortgage REIT, Inc. is a U.S.-based real estate investment trust focused on investing in residential mortgage assets, including non-agency mortgage-backed securities, residential mortgage loans, and credit-linked real estate instruments. It serves U.S. institutional and retail investors, targeting competitive risk-adjusted returns through regular income and long-term capital growth.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
AOMR vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.9M | $13.8M |
| Net Profit | $11.3M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | — | -18.5% |
| Net Margin | 103.9% | -34.7% |
| Revenue YoY | 10.4% | 73.8% |
| Net Profit YoY | 175.2% | -141.1% |
| EPS (diluted) | $0.44 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $10.9M | $13.8M | ||
| Q3 25 | $10.2M | $12.5M | ||
| Q2 25 | $9.9M | $9.7M | ||
| Q1 25 | $10.1M | $8.8M | ||
| Q4 24 | $9.9M | $7.9M | ||
| Q3 24 | $9.0M | $7.0M | ||
| Q2 24 | $9.5M | $7.3M | ||
| Q1 24 | $8.6M | $25.4M |
| Q4 25 | $11.3M | $-4.8M | ||
| Q3 25 | $11.4M | $-638.0K | ||
| Q2 25 | $767.0K | $-3.2M | ||
| Q1 25 | $20.5M | $-1.2M | ||
| Q4 24 | $-15.1M | $-2.0M | ||
| Q3 24 | $31.2M | $-5.7M | ||
| Q2 24 | $-273.0K | $-5.6M | ||
| Q1 24 | $12.9M | $12.8M |
| Q4 25 | — | -18.5% | ||
| Q3 25 | — | -1.5% | ||
| Q2 25 | 7.7% | -28.3% | ||
| Q1 25 | — | -9.2% | ||
| Q4 24 | -152.6% | -11.8% | ||
| Q3 24 | — | -74.6% | ||
| Q2 24 | -1.4% | -69.4% | ||
| Q1 24 | — | 54.2% |
| Q4 25 | 103.9% | -34.7% | ||
| Q3 25 | 112.1% | -5.1% | ||
| Q2 25 | 7.7% | -32.7% | ||
| Q1 25 | 203.5% | -13.3% | ||
| Q4 24 | -152.6% | -25.0% | ||
| Q3 24 | 345.9% | -82.2% | ||
| Q2 24 | -2.9% | -76.5% | ||
| Q1 24 | 150.1% | 50.6% |
| Q4 25 | $0.44 | $-0.17 | ||
| Q3 25 | $0.46 | $-0.02 | ||
| Q2 25 | $0.03 | $-0.11 | ||
| Q1 25 | $0.87 | $-0.04 | ||
| Q4 24 | $-0.62 | $-0.02 | ||
| Q3 24 | $1.29 | $-0.21 | ||
| Q2 24 | $-0.01 | $-0.20 | ||
| Q1 24 | $0.51 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.6M | $36.8M |
| Total DebtLower is stronger | $2.3B | — |
| Stockholders' EquityBook value | $267.5M | $35.5M |
| Total Assets | $2.7B | $70.6M |
| Debt / EquityLower = less leverage | 8.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.6M | $36.8M | ||
| Q3 25 | $51.6M | $21.9M | ||
| Q2 25 | $40.5M | $18.7M | ||
| Q1 25 | $38.7M | $22.7M | ||
| Q4 24 | $40.8M | $26.6M | ||
| Q3 24 | $42.1M | $40.3M | ||
| Q2 24 | $44.0M | $43.1M | ||
| Q1 24 | $39.4M | $51.2M |
| Q4 25 | $2.3B | — | ||
| Q3 25 | $2.2B | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | $1.8B | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $267.5M | $35.5M | ||
| Q3 25 | $264.2M | $-4.5M | ||
| Q2 25 | $246.4M | $-7.5M | ||
| Q1 25 | $251.5M | $-5.9M | ||
| Q4 24 | $239.0M | $-5.9M | ||
| Q3 24 | $265.1M | $-5.2M | ||
| Q2 24 | $255.8M | $-1.4M | ||
| Q1 24 | $263.3M | $3.0M |
| Q4 25 | $2.7B | $70.6M | ||
| Q3 25 | $2.6B | $49.3M | ||
| Q2 25 | $2.6B | $44.9M | ||
| Q1 25 | $2.7B | $46.4M | ||
| Q4 24 | $2.3B | $44.9M | ||
| Q3 24 | $2.3B | $58.9M | ||
| Q2 24 | $2.1B | $63.2M | ||
| Q1 24 | $2.3B | $69.2M |
| Q4 25 | 8.51× | — | ||
| Q3 25 | 8.37× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.62× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-407.0M | $-6.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -35.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-407.0M | $-6.0M | ||
| Q3 25 | $-173.4M | $1.5M | ||
| Q2 25 | $20.6M | $-3.7M | ||
| Q1 25 | $-201.7M | $-4.3M | ||
| Q4 24 | $-221.5M | $-1.5M | ||
| Q3 24 | $-212.4M | $-2.2M | ||
| Q2 24 | $-24.2M | $-8.4M | ||
| Q1 24 | $40.2M | $39.0M |
| Q4 25 | -35.96× | — | ||
| Q3 25 | -15.19× | — | ||
| Q2 25 | 26.92× | — | ||
| Q1 25 | -9.83× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.81× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 3.12× | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AOMR
| Nonrelated Party | $6.4M | 59% |
| Other | $4.5M | 41% |
FENC
Segment breakdown not available.
